Core Viewpoint - The report from Zhongyou Securities indicates that Ruimaite achieved a net profit attributable to the parent company of 131 million yuan in the first half of the year, representing a year-on-year increase of 42.19% [1] Financial Performance - In Q2, the net profit attributable to the parent company was 59 million yuan, showing a year-on-year growth of 39.92% [1] - The company experienced double growth in revenue and profit for the first half of 2025, primarily due to contributions from both domestic and overseas markets [1] Overseas Market Performance - The overseas revenue for the first half of the year reached 353 million yuan, marking a year-on-year increase of 61.33% [1] - The inventory destocking cycle in the U.S. ventilator market has ended, leading to a stabilization of the market [1] - In Europe, the cloud platform construction has been largely completed, and through localized operational strategies, the company's products have begun to enter the mainstream medical insurance market, which is expected to provide significant growth momentum in the future [1] Domestic Market Performance - Domestic revenue for the first half of the year was 191 million yuan, reflecting a year-on-year increase of 16.87% [1] - The company has adjusted its channel and sales policies in the domestic market, which has begun to show positive results [1] - The proportion of consumables business continues to increase [1] Future Strategy - The company plans to continuously enhance ventilator production capacity while simultaneously advancing the consumables business [1] - More resources will be allocated to comprehensively increase the revenue share of the consumables business, aiming for synergistic development between complete machines and consumables [1]

1 | | 住所 | | 珠海市横琴新区下村52号六楼 | | | | --- | --- | --- | --- | --- | --- | | | 信息披露义务人2 | | 上海盛旻创业投资合伙企业（有限合伙） | | | | | 住所 | | 上海市闵行区庙泾路66号F425室 | | | | | 信息披露义务人3 | | 南京合灏创业投资企业（有限合伙） | | | | | 住所 | | 江苏省南京市溧水区石湫街道科创中心 | | | | | 权益变动时间 | | 2025年8月12日至2025年9月24日 | | | | | 股票简称 瑞迈特 | | 股票代码 301367 | | | | | 变动类型（可 增加□ 多选） | 减少☑ | 一致行动人 有☑ | | 无□ | | | 是否为第一大股东或实际控制人 | | | 是□ 否☑ | | | | 2.本次权益变动情况 | | | | | | | 股份种类（A股、B股等） | | 减持股数（万股） | 减持比例（%） | | | | A股 | | 89.5989 | 1.00 | | | | 其中：集中竞价 | | 31.1089 | 0.35 ...

Core Viewpoint - The stock price of Ruimait has shown a significant increase of 35.98% year-to-date, despite recent declines in the short term, indicating volatility in the market [2]. Company Overview - Ruimait Medical Technology Co., Ltd. specializes in the research, production, and sales of medical devices and consumables in the respiratory health sector, primarily targeting patients with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [2]. - The company was established on July 27, 2001, and went public on November 1, 2022 [2]. - The revenue composition includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [2]. Financial Performance - For the first half of 2025, Ruimait reported a revenue of 544 million yuan, representing a year-on-year growth of 42.30%, and a net profit attributable to shareholders of 131 million yuan, also reflecting a growth of 42.19% [3]. - As of June 30, 2025, the number of shareholders decreased by 24.87% to 6,850, while the average circulating shares per person increased by 33.11% to 8,251 shares [3]. Market Activity - On September 24, Ruimait's stock price rose by 2.04% to 85.13 yuan per share, with a trading volume of 42.52 million yuan and a turnover rate of 0.89%, resulting in a total market capitalization of 7.628 billion yuan [1]. - The net outflow of main funds was 1.355 million yuan, with large orders accounting for 10.85% of purchases and 14.03% of sales [1]. Shareholder and Dividend Information - Since its A-share listing, Ruimait has distributed a total of 228 million yuan in dividends [4]. - As of June 30, 2025, Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders [4].

Core Insights - The company reported a significant increase in both revenue and net profit for the first half of 2025, with revenue reaching 544 million yuan, a year-on-year increase of 42.30%, and net profit attributable to the parent company at 131 million yuan, up 42.19% [1] - The growth in revenue and profit is attributed to contributions from both domestic and international markets, with international revenue showing a notable increase [2] Financial Performance - In H1 2025, the company achieved revenue of 544 million yuan, with a net profit of 131 million yuan, and a net profit excluding non-recurring gains of 99 million yuan, reflecting increases of 42.30%, 42.19%, and 49.34% respectively [1] - For Q2 2025, the company reported revenue of 279 million yuan, a year-on-year increase of 46.54%, and a net profit of 59 million yuan, up 39.92% [1] Market Analysis - The international market contributed significantly to revenue growth, with overseas revenue reaching 353 million yuan, a year-on-year increase of 61.33%. The U.S. ventilator market has stabilized, and the European market has completed cloud platform construction, enhancing growth potential [2] - Domestic revenue was 191 million yuan, reflecting a year-on-year increase of 16.87%, supported by adjustments in channel and sales policies [2] Business Segmentation - The consumables business accounted for approximately 30% of total revenue in H1 2025. This segment has a higher replacement frequency and profit margin compared to ventilators, which is expected to enhance overall profitability [2] - The company plans to increase ventilator production capacity while simultaneously advancing the consumables business to achieve synergistic growth [2] Profit Forecast - Revenue projections for 2025-2027 are estimated at 1.138 billion yuan, 1.403 billion yuan, and 1.689 billion yuan, with year-on-year growth rates of 34.92%, 23.24%, and 20.40% respectively [3] - Net profit forecasts for the same period are 264 million yuan, 355 million yuan, and 435 million yuan, with corresponding growth rates of 69.62%, 34.67%, and 22.66% [3] - The projected price-to-earnings (PE) ratios for 2025-2027 are 29.07, 21.59, and 17.60, with PEG ratios of 0.42, 0.62, and 0.78, indicating a "buy" rating [3]

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative increase in stock price of over 20% compared to the benchmark index within six months [5][13]. Core Insights - The company reported a significant revenue increase of 42.30% year-on-year for H1 2025, reaching 544 million yuan, with a net profit of 131 million yuan, also up by 42.19% [3][4]. - The growth in revenue is attributed to both domestic and international markets, with international revenue growing by 61.33% and domestic revenue by 16.87% [4]. - The consumables segment is becoming increasingly important, accounting for approximately 30% of total revenue in H1 2025, which is expected to enhance profitability due to higher replacement frequency and margins [4]. Financial Performance - For the forecast period of 2025-2027, the company is expected to achieve revenues of 1.138 billion yuan, 1.403 billion yuan, and 1.689 billion yuan, with year-on-year growth rates of 34.92%, 23.24%, and 20.40% respectively [5][9]. - The net profit attributable to the parent company is projected to be 264 million yuan, 355 million yuan, and 435 million yuan for the same period, with growth rates of 69.62%, 34.67%, and 22.66% respectively [5][9]. - The company's price-to-earnings (P/E) ratio is expected to decrease from 29.07 in 2025 to 17.60 in 2027, indicating improving valuation metrics [5][9].

Core Viewpoint - The company has not yet engaged in any collaboration with Brain Tiger Technology despite signing a confidentiality agreement nearly six months ago [1] Summary by Categories - **Company Progress** - The company stated that there has been no relevant cooperation with Brain Tiger Technology as of September 24 [1] - **Future Disclosure** - The company will strictly adhere to relevant laws and regulations for any future disclosures regarding potential collaborations [1]

Investment Rating - The report maintains an "Outperform" rating for the biopharmaceutical industry [1] Core Viewpoints - The growth of healthcare expenses, which reached 9.06 trillion yuan in 2023, is outpacing GDP growth, indicating that commercial health insurance may provide a solution to the pressures faced by the medical insurance system [3][15] - The commercial health insurance sector is expected to grow significantly, with premiums projected to reach 97.74 billion yuan by 2024, driven by low penetration rates and the need for additional funding sources [20][24] - Policies are increasingly supportive of commercial health insurance, particularly in relation to innovative drugs, which are now being included in the commercial health insurance directory [71][76] Summary by Sections Part 1: Healthcare Financing System - The healthcare financing system in China consists of government, social, and personal contributions, with social contributions being the main driver for future growth [10][15] Part 2: Growth of Health Insurance - The commercial health insurance market is expected to fill a significant funding gap, with an estimated shortfall of over 1.7 trillion yuan by 2030 [21][22] - Medical insurance is the primary source of compensation within commercial health insurance, with a compensation rate of approximately 68.79% in 2022 [27][31] Part 3: Core Products of Medical Insurance - The report highlights the importance of medical insurance as a key focus area, noting that it directly compensates for medical expenses, unlike critical illness insurance [31][35] Part 4: Policy Support for Health Insurance Development - A series of policies since 2009 have aimed to promote the development of commercial health insurance, with specific targets for market size and coverage [71][72] Part 5: Investment Recommendations - The report suggests focusing on innovative drug companies with rich pipelines, DTP pharmacies, and companies in the TPA industry, as well as innovative medical devices and high-end medical service providers [77]

Group 1 - The core viewpoint of the news is that Ruimait has experienced a decline in stock price, with a cumulative drop of 6.36% over four consecutive days, currently trading at 85.52 yuan per share [1] - Ruimait Medical Technology Co., Ltd. specializes in the research, production, and sales of medical devices and consumables in the respiratory health field, primarily serving patients with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [1] - The company's main business revenue composition includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [1] Group 2 - According to data, Nord Fund holds a significant position in Ruimait, with its Nord Small and Mid-Cap Mixed Fund (570006) owning 18,000 shares, accounting for 5.02% of the fund's net value [2] - The fund has incurred a floating loss of approximately 10.46 million yuan during the four-day decline [2] - The Nord Small and Mid-Cap Mixed Fund has achieved a return of 45% year-to-date, ranking 1247 out of 8244 in its category [2]

| 保荐人名称：中国国际金融股份有限公司 | 被保荐公司简称：瑞迈特 | | --- | --- | | 保荐代表人姓名：陈婷婷 | 联系电话：010-65051166 | | 保荐代表人姓名：杨 桐 | 联系电话：010-65051166 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 次 | | 2.督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不 | | | 限于防止关联方占用公司资源的制度、募集资金管 | 是 | | 理制度、内控制度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 次（每月一次） 6 | | （2）公司募集资金项目进展是否与信息披露文件 | 是 | | 一致 | | | 4.公司治理督导情况 | | | （1）列席公司股东大会次数 | 未列席，已事前审 ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于北京瑞迈特医疗科技股份有限公司 2025 年第二次临时股东会的 法律意见书 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》 （以下简称"《股东会规则》"）、《律师事务所从事证券法律业务管理办法》 （以下简称"《证券法律业务管理办法》"）、《律师事务所证券法律业务执业 规则（试行）》（以下简称"《证券法律业务执业规则》"）等相关法律、行政 法规、规章、规范性文件及《北京瑞迈特医疗科技股份有限公司章程》（以下简 称"《公司章程》"）的规定，就本次会议的召集与召开程序、召集人资格、出 席会议人员资格、会议表决程序及表决结果等事宜，出具本法律意见书。 对本法律意见书的出具，本所律师特作如下声明： 1．本所律师仅就本次会议的召集与召开程序、召集人和出席现场会议人员 资格、会议表决程序及表决结果的合法性发表意见，不对本次会议所审议的议案 内容及该 ...